Janssen Research & Development, LLC
(Janssen) announced today new findings from PSUMMIT II, a Phase 3
investigational study that showed patients with active psoriatic arthritis,
including those previously treated with one to five tumor necrosis factor
(TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA^®
(ustekinumab) demonstrated significant improvements in signs and symptoms of
the disease. Significantly more patients receiving either STELARA 45 mg or 90
mg achieved at least a 20 percent improvement in signs and symptoms according
to American College of Rheumatology criteria (ACR 20) at week 24, the primary
endpoint, than did patients receiving placebo regardless of background
methotrexate use. During a late-breaker session of PSUMMIT 1, the initial
Phase 3 study, investigators will present 52-week data that showed improvement
in efficacy of STELARA over time in treating signs and symptoms of the
disease. These data are being presented at the 2012 Annual Meeting of the
American College of Rheumatology.
In the Phase 3 Multicenter, Randomized, Double-blind, Placebo‑controlled trial
of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,
Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis
Including Those Previously Treated with Biologic Anti-TNF-alpha Agent(s)
(PSUMMIT II) study, patients with active psoriatic arthritis despite treatment
with disease-modifying antirheumatic drugs (DMARDs), nonsteroidal
anti-inflammatory drugs (NSAIDs) and/or anti-TNF-alpha therapy (not intended
as a superiority or comparative claim versus TNF inhibitors) were randomized
to receive subcutaneous STELARA 45 mg or 90 mg or placebo at weeks 0, 4 and
then every 12 weeks. At week 24, the primary endpoint was met as
statistically significantly greater proportions of patients achieving ACR 20
responses (a standard measure of improvement in disease activity) were
observed in patients receiving STELARA 45 mg (43.7 percent of patients) or
STELARA 90 mg (43.8 percent of patients) compared with 20.2 percent of
patients receiving placebo (P < 0.001 for both comparisons). Among patients
previously treated with TNF inhibitors, 36.7 percent of patients and 34.5
percent of patients receiving STELARA 45 mg or 90 mg, respectively, achieved
ACR 20 at week 24 compared with 14.5 percent of patients receiving placebo (P
= 0.006 for STELARA 45 mg, P = 0.011 for STELARA 90 mg).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in